Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab combination study in diffuse large B-cell lymphoma
jRCT2011220044Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of epcoritamab in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Dose Limiting Toxicities. Started Aug 2023; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2011220044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220044.